ENTA — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

7.86

Margin Of Safety %

Put/Call OI Ratio

0.24

EPS Next Q Diff

-0.07

EPS Last/This Y

1.71

EPS This/Next Y

-0.08

Price

13.42

Target Price

18.71

Analyst Recom

1.43

Performance Q

-3.45

Upside

-934.0%

Beta

1.01

Ticker: ENTA

16 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	ENTA	13.88	0.20	0.40	1250
2026-03-10	ENTA	13.92	0.20	0.40	1250
2026-03-11	ENTA	14.15	0.20	0.40	1250
2026-03-12	ENTA	13.42	0.20	0.40	1250
2026-03-13	ENTA	13.41	0.20	0.40	1250
2026-03-17	ENTA	13.31	0.23	999.99	1282
2026-03-18	ENTA	12.68	0.24	0.83	1293
2026-03-20	ENTA	12.55	0.15	999.99	1223
2026-03-25	ENTA	12.18	0.22	3.67	1164
2026-03-26	ENTA	12.55	0.23	999.99	1178
2026-03-27	ENTA	12.19	0.23	999.99	1178
2026-03-30	ENTA	12.16	0.23	999.99	1178
2026-03-31	ENTA	12.61	0.23	999.99	1178
2026-04-01	ENTA	12.93	0.23	999.99	1178
2026-04-06	ENTA	13.23	0.25	0.04	1196
2026-04-07	ENTA	13.42	0.24	0.00	1240
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

16 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	ENTA	13.88	52.1	-	-2.13
2026-03-10	ENTA	13.95	52.1	-	-2.13
2026-03-11	ENTA	14.13	52.1	-	-2.13
2026-03-12	ENTA	13.46	52.1	-	-2.13
2026-03-13	ENTA	12.69	52.1	-	-2.13
2026-03-17	ENTA	13.27	52.1	-	-2.13
2026-03-18	ENTA	12.73	52.1	-	-2.13
2026-03-19	ENTA	13.03	52.1	-	-2.13
2026-03-20	ENTA	12.51	52.1	-	-2.13
2026-03-23	ENTA	12.66	52.1	-	-2.13
2026-03-24	ENTA	12.10	52.1	-	-2.13
2026-03-25	ENTA	12.19	52.1	-	-2.13
2026-03-26	ENTA	12.49	52.1	-	-2.13
2026-03-27	ENTA	12.19	52.1	-	-2.13
2026-03-30	ENTA	12.17	52.1	-	-2.13
2026-03-31	ENTA	12.61	52.1	-	-2.13
2026-04-01	ENTA	12.94	52.1	-	-2.13
2026-04-02	ENTA	13.13	52.1	-	-2.13
2026-04-06	ENTA	13.23	52.1	-	-2.13
2026-04-07	ENTA	13.42	52.1	-	-2.13
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	ENTA	-0.86	18.15	8.27
2026-03-10	ENTA	-0.86	18.15	8.27
2026-03-11	ENTA	-0.86	18.15	7.94
2026-03-12	ENTA	-0.86	18.15	7.94
2026-03-13	ENTA	-0.86	18.15	7.94
2026-03-18	ENTA	-0.86	18.10	7.94
2026-03-19	ENTA	-0.86	18.10	7.94
2026-03-20	ENTA	-0.86	18.10	7.94
2026-03-23	ENTA	-0.86	18.11	7.94
2026-03-24	ENTA	-0.86	18.11	7.94
2026-03-25	ENTA	-0.86	18.11	7.86
2026-03-26	ENTA	-0.86	18.11	7.86
2026-03-27	ENTA	-0.86	18.11	7.86
2026-03-30	ENTA	-0.86	18.24	7.86
2026-03-31	ENTA	-0.86	18.24	7.86
2026-04-01	ENTA	-0.86	18.24	7.86
2026-04-02	ENTA	-0.86	18.24	7.86
2026-04-06	ENTA	-0.86	18.24	7.86
2026-04-07	ENTA	-0.86	18.24	7.86
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.42

Avg. EPS Est. Current Quarter

-0.51

Avg. EPS Est. Next Quarter

-0.49

Insider Transactions

-0.86

Institutional Transactions

18.24

Beta

1.01

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

86.8

Max Drawdown 5-Year %

-95.6

Target Price

18.71

P/E

Forward P/E

PEG

P/S

5.82

P/B

3.08

P/Free Cash Flow

EPS

-3.2

Average EPS Est. Cur. Y

-2.13

EPS Next Y. (Est.)

-2.21

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-106.8

Relative Volume

0.48

Return on Equity vs Sector %

-84

Return on Equity vs Industry %

-67.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.22

EBIT Estimation

◆ ENTA Healthcare

$13.43

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

8/20

Pullback

11/25

Volume

11/15

Valuation

9/20

TP/AR

2/10

Options

7/10

RSI

Range 1M

65.9%

Sup Dist

4.4%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

24/30

Estimates

0/20

Inst/Vol

6/15

Options

8/10

EPS Yr

35.7%

EPS NY

19.4%

52W%

71.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +39.3% upside

Quality

6/30

Valuation

10/30

Growth

17/25

Stability

6/10

LT Trend

2/5

Upside

+39.3%

Quality

Enanta Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 120

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

ENTA

Latest News

—

Caricamento notizie per ENTA…

stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today

news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance

stock history ENTA – Enanta Pharmaceuticals Inc invest stock market

stock prices ENTA premarket after hours

ticker ENTA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ENTA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y